Takeda Pharmaceutical (TAK) Net Income Growth (3y) (2020 - 2026)
Takeda Pharmaceutical (TAK) Net Income Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -27.09% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -86.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.33% |
| Mar 31, 2026 | -4.58% |
| Dec 31, 2025 | -93.32% |
| Sep 30, 2025 | 78.55% |
| Jun 30, 2025 | -8.42% |
| Mar 31, 2025 | -22.02% |
| Dec 31, 2024 | -49.05% |
| Sep 30, 2024 | 50.26% |
| Jun 30, 2024 | -25.96% |
| Mar 31, 2024 | 15.49% |
| Dec 31, 2023 | -73.36% |
| Sep 30, 2023 | 158.29% |
| Jun 30, 2023 | -7.31% |
| Mar 31, 2023 | -18.06% |
| Sep 30, 2022 | 59.22% |
| Jun 30, 2022 | 136.74% |
| Mar 31, 2022 | 144,003.41% |
| Dec 31, 2021 | 14.42% |
| Sep 30, 2021 | 96,851.79% |
| Jun 30, 2021 | 40.94% |